Abstract-The cardiohemodynamic effects of nipradilol (K-351) were studied in comparison with those of propranolol, nadolol and prazosin in anesthetized, open chest dogs. All drugs were administered intravenously.
Nipradilol
(K-351) is a unique beta adrenoceptor blocking agent because it possesses a nitroxy group in its chemical structure (1) . The nitroxy group was incor porated into the chemical structure with the aim of making the compound possess a nitroglycerin-like action in addition to a beta adrenoceptor blocking action (1) . In the treatmen': of patients with angina pectoris, hypertension or both, such a beta adrenoceptor blocking agent would be superior to hitherto known beta-adrenoceptor blocking agents that block beta-adre noceptors alone. This is because increases in coronary arterial resistance and total peri pheral resistance by beta-adrenoceptor blocking agents, particularly seen in the acute phase, are their main drawbacks. If the drug reduces the preload as nitroglycerin does, this property is also favorable as an antianginal agent. Nipradilol has been shown to be only about 2 times as potent as pro * To whom correspondence should be addressed .
pranolol in producing a non-selective beta adrenoceptor blocking effect in isolated guinea-pig atria and trachea (1) . Never theless, nipradilol, unlike propranolol, pro duces a definite hypotensive effect in spon taneously hypertensive and DOCA hyper tensive rats after acute oral administration, suggesting that it possesses some types of vasodilator action (1, 2) . The direct relaxant action of nipradilol on vascular smooth muscle has been demonstrated in isolated arteries and veins (1, 3) . However, these findings are unable to settle the question of whether the hypotensive and vascular relaxant action of nipradilol can be ascribed to its nitroglycerin-like action. The following findings are highly suggestive of the nitro glycerin-like action of nipradilol: Unlike pro pranolol, nipradilol decreased left ventricular end-diastolic pressure (LVEDP) in anes thetized dogs (4) . This is remarkable in view of the fact that nipradilol has a certain degree of negative inotropic and non-specific mem brane stabilizing actions (1, 5) . Nipradilol also decreased central venous pressure previously raised with dihydroergotamine in pithed rats, suggesting the reduced venous return (VR) through its dilator effect on capacitance vessels (6) . However, so far no experimental data are available about whether nipradilol really produces a reduction of VR and consequently a reduction of cardiac output (COP). The present study was carried out to elucidate whether nipradilol mimics nitroglycerin or other nitrates in cardiohemodynamic effects par ticularly in its effects on VR and right atrial pressure (RAP) in anesthetized, open-chest dogs. The effects of propranolol, nadolol and prazosin were also investigated in order to estimate the possible contribution of alpha or beta-adrenoceptor blocking action to the cardiohemodynamic effects of nipradilol, because nipradilol has also been shown to possess a weak alpha-adrenoceptor blocking action (1).
Materials and Methods
Experiments were performed on young mongrel dogs of both sexes weighing 7 to 11 kg which were free from filarial infection. The preparation was essentially the same as had been used by Kokubun et al. (7) and Imai et al. (8) . The animals were anesthetized with sodium pentobarbital initially at a dose of 30 mg/kg, i.v., and hourly at a main tenance dose of 4 to 5 mg/kg, i.v. Under artificial respiration with room air in a tidal volume of 20 ml/kg at a rate of 18 breaths/ min by the use of a dog respirator (Harvard Apparatus, Model 607), the chest was opened by mid-sternal incision. The azygos vein was ligated and both phrenic nerves were cut. The heart was kept in position by the pericardial cradle. Non-cannulating probes of a 2-channel electromagnetic flowmeter (Nihon Kohden, MF-27) were fitted to the superior and inferior vena cavae to measure the mean blood flow through the two vessels. The mean blood flow through the pulmonary trunk was also measured with another non-cannulating probe of a 1 channel electromagnetic flowmeter (Nihon Kohden, MFV-1200). The mean right atrial pressure was measured with a pressure transducer (Nihon Kohden, LPU-0.1). The zero base line reference for the RAP was set equal to the level of the tricuspid valve. These 4 variables were recorded on a 4-channel rectilinear recorder (Watanabe Sokki, Linear Corder Mark 3). The systemic blood pressure was measured at the femoral artery with a pressure transducer (Statham, P-50). The heart rate was measured with a cardio tachometer (Sanei, type 2140) which was triggered by the R wave of lead II electro cardiograms.
These two variables were recorded on a 6-channel rectilinear recorder (Sanei, 8S). The zero flow level in each probe was simultaneously determined at the end of the experiment when the cardiac arrest was abruptly produced by a rapid injection of saturated KCI solution.
The drugs used were as follows: Nipradilol (Kowa), (+)-propranolol hydrochloride (Kowa), (±)-nadolol (Squibb) and prazosin hydrochloride (Pfizer Taito). Nipradilol and nadolol were dissolved in 0.1 N HCI to give a concentration of 30 mg/ml, and propranolol was dissolved in 0.9% saline at a concen tration of 10 mg/ml. These drug solutions were diluted with 0.9% saline to the desired concentrations.
Prazosin was dissolved in distilled water to give a concentration of 0.5 mg/ml and then diluted with distilled water. All the drugs were injected into the femoral vein in doses of 1, 2, 7, 20, 70, 200 and 700 iig/kg at 10 min intervals. These doses cor respond to the cummulative doses of 1, 3, 10, 30, 100, 300 and 1000 /,,g/kg, respectively. Doses of drugs refer to their bases.
Values of changes in cardiohemodynamic variables used for construction of dose response curves refer to those just before administration of the next dose. Statistical significance of difference between mean values was evaluated by Student's paired t-test. A P value of less than 0.05 was considered to be significant.
Results
Control values of 9 cardiohemodynamic variables: The control values of 9 cardio hemodynamic variables in 20 dogs are presented in Table 1 . The pulmonary arterial blood flow (PAF) which represents the total COP was within a range from 600 to 1000 ml/min. The blood flow through the inferior vena cava (IVCF) and the superior vena cava (SVCF) ranged from 400 to 700 and 100 to 300 ml/min, respectively. The VR which is the sum of the IVCF and SVCF was within the same range as the PAF. The RAP and the heart rate (HR) ranged from 1 5 to 30 mmH2O and 100 to 170 beats/min, respectively. The systolic (SBP), diastolic (DBP) and mean blood pressure (MBP) ranged from 100 to 170, 60 to 120 and 80 to 130 mmHg, respec tively. Effects of nipradilol on cardiohemodyn amics: The effects of cumulative intravenous injections of nipradilol (1-1000 iig/kg) were studied in 5 dogs. A typical experiment is shown in Fig. 1 Effects of propranolol on cardiohemody namics: The effects of propranolol (1-1000 !ig/kg, i.v.), a non-selective beta-adre noceptor blocking agent, were examined in 5 dogs, and data are summarized in Fig. 3 . Propranolol had virtually no effects on the SBP, DBP and MBP. The PAF tended to decrease with increasing doses, but decreases were not statistically significant except for the largest dose (1000 iig/kg). There also were small decreases in IVCF and VR, although these changes were not statistically significant. The decrease in VR produced by 1000 ,ug/kg of propranolol was 100±64 ml/ min, which was much smaller than that produced by the same dose of nipradilol. The SVCF did not change in all the doses examined.
Unlike nipradilol, propranolol caused a dose-dependent increase in RAP; with a dose of 1000 /-,g/kg, the RAP increased by 8.8±2.4 mmH2O. The HR decreased in a dose-dependent manner in doses of 3-1000 fig/kg . Effects of nadolol on cardiohemody namics: The effects of nadolol (1-1000 ,rig/ kg, i.v.), a non-selective beta-adrenoceptor blocking agent which lacks a direct cardio depressant action (9), were studied in 5 dogs, and results are summarized in Fig. 4 . Nadolol did not change the SBP, DBP and MBP in all the doses examined. The PAF and IVCF decreased moderately in doses of 3-1000 /q/kg, and the SVCF decreased in doses of 30 and 100 /cg/kg. The VR decreased in doses of 1-1000 /tg/kg, but even at the largest dose, the decrease remained only by 140±21 ml/min, which was considerably smaller than that produced by nipradilol. Despite lack of a direct cardiodepressant action, nadolol produced a significant increase in RAP in doses of 3 even with increasing doses up to 1000 /cg/ kg. The IVCF and VR decreased moderately in doses of 3-1000 / g/kg, and at the largest dose (1000 /ag/kg), the VR decreased by 126±36 ml/min, although these variables increased transiently after dosing. The PAF and SVCF behaved similarly to the IVCF and VR. The RAP tended to decrease in doses of 3-1000 ,ug/kg, but the changes were not statistically significant. The H R remained unchanged in all the doses examined.
Comparison of the effects of nipradilol, propranolol, nadolol and prazosin on the relation between the VR and RAP: Since the RAP is one of the determinants of the VR, the correlation between changes in RAP and those in VR was examined. In Fig. 6 , changes in RAP caused by the drugs are plotted against those in VR. Nipradilol markedly decreased the VR, but caused virtually no change in RAP; and as a result, there was no significant correlation between the VR and RAP (r=0.057).
Propranolol produced a slight decrease in VR which was accompanied by a marked increase in RAP. Consequently, there was a negative correlation between the VR and RAP (r=-0.483, P<0.05). Nadolol also decreased the VR and increased the RAP, but there was no statistically significant correlation between the VR and RAP (r=-0.062).
Prazosin caused simultaneous decreases in VR and RAP, although these changes were rather small and statistically insignificant. Thus, there was a positive correlation between the VR and RAP (r=0.756, P<0.001).
Effects of propranolol, nadolol and prazosin on cardiohemodynamic changes produced by nipradilol: The effects of pro pranolol, nadolol and prazosin on changes in cardiohemodynamic variables produced by nipradilol were further investigated to look into possible involvements of beta and/or alpha-adrenoceptor blocking activities in the effects of nipradilol. Figure 7 shows the effect of propranolol (1 mg/kg, i.v.), nadolol (1 mg/kg, i.v.) or prazosin (1 mg/kg, i.v.) on changes in SBP, DBP, MBP and HR caused by nipradilol. After propranolol, nadolol or prazosin, nipradilol still produced a dose dependent hypotensive effect in doses of 10-1000 ,ug/kg; however, the decrease in SBP produced by 300 ug/kg of nipradilol was slightly attenuated after prazosin. The bradycardia produced by nipradilol was nearly abolished by propranolol or nadolol, whereas prazosin failed to affect the brady cardic effect of nipradilol. Figure 8 illustrates the effects of propranolol, nadolol and prazosin on the changes in PAF, IVCF, SVCF, VR and RAP produced by nipradilol. The decreases in PAF, IVCF and VR produced by nipradilol were scarcely affected by pro pranolol or nadolol. After prazosin, nipradilol still caused definite decreases in PAF, IVCF and VR; however, the decreases in IVCF caused by large doses (300 and 1000 fig/kg ) of nipradilol were somewhat attenuated by prazosin. Although nipradilol per se was without effect on the RAP, it did cause a significant decrease in RAP after beta adrenoceptor blockade with propranolol or nadolol. In contrast, after prazosin, the RAP was slightly increased by nipradilol.
Discussion
In the present experiments, nipradilol produced decreases in BP, HR and PAF which is equivalent to the COP, but failed to change the RAP. These results are largely consistant with those obtained by previous workers from anesthetized dogs (4); in their experiments, nipradilol decreased the BP, HR, mean aortic flow and LVEDP. The principal finding of the present experiments was a profound decrease in VR by nipradilol which had not been directly demonstrated so far, although circumstantial evidence has suggested it.
From the comparative study, it became evident that nipradilol differed from current beta-adrenoceptor blocking agents like pro pranolol and nadolol in the following respects:
Firstly, nipradilol produced an immediate and marked decrease in BP, whereas propranolol and nadolol did not. Secondly, nipradilol caused a striking decrease in VR which was much greater than those produced by propranolol and nadolol: e.g., at 1 mg/kg the decrease in VR by nipradilol was about 46% as against only about 14% and 19% by propranolol and nadolol, respectively. Thirdly, nipradilol did not change the RAP which is one of indices of contractility of the heart, whereas pro pranolol and even nadolol which has no direct cardiodepressant action (9) increased the RAP significantly.
It has been widely accepted that as an acute effect, beta-adrenoceptor blocking agents decrease the COP in man. Experi ments on anesthetized dogs (10, 11) have demonstrated that the decrease in COP by beta-adrenoceptor blocking agents is due to the decreased VR. This decrease has been ascribed to an increase in transhepatic venous resistance due to beta-adrenoceptor blockade (10). In the present experiments, too, the two beta-adrenoceptor blocking agents nadolol and nipradilol definitely reduced the VR, and propranolol also tended to do so. Thus, the decrease in VR by these agents would be atributed at least in part to the beta-adrenoceptor blockade per se. However, the decrease in VR produced by nipradilol was greater than those produced by the other beta-adrenoceptor blocking agents.
Therefore, additional mechanisms must be involved in the greater decrease in VR produced by nipradilol.
It has been shown that, although weak, nipradilol possesses an alpha-adrenoceptor blocking action (1) . Therefore, a possible involvement of this mechanism should be argued.
In the present experiments, the alpha, -adrenoceptor blocking agent, prazosin decreased the VR. The observed decrease in VR by prazosin may be attributable to venodilatation resulting from alpha, adrenoceptor blockade, i.e., an increase in venous capacitance. Indeed, prazosin has been reported to dilate more effectively dorsal hand veins than forearm arteries in man both of which were contracted by noradre naline (12). The extent of decrease in VR by prazosin, however, was only about 17% of the control value even with its largest dose (1 mg/kg) as against about 46% by the largest dose (1 mg/kg) of nipradilol. Moreover, in producing alpha-adrenoceptor blockade nipradilol is far less potent than prazosin (13). Thus, it is unlikely that alpha adrenoceptor blockade by nipradilol, if any, is greatly involved in the decreased VR.
Alternatively, it is highly likely that another mechanism would be responsible for the reduction of VR by nipradilol. This sup position has become more plausible through the present findings that nipradilol definitely decreased the VR even after propranolol, nadolol or prazosin. It is noteworthy that nipradilol, which scarcely affected the RAP when given alone, caused a decrease in RAP after propranolol or nadolol. Concomitant decreases in VR and RAP by nipradilol after beta-adrenoceptor blockade are very much similar to what has been observed with nitroglycerin (7). As described in the intro duction section, nipradilol possesses the nitroxy group, and it has been reported that like nitroglycerin, nipradilol dilates pre ferentially !arge conductive coronary arteries (1). Thus, a reduction of VR by nipradilol appears in all probability to be due to its rather preferential dilator action on capaci tance vessels.
Another characteristic of nipradilol was a marked hypotensive effect. Here should be argued a role of the effect of nipradilol on the arterial side in producing acute hypotension. Possible mechanisms involved in acute hypo tension would be its alpha-adrenoceptor blocking (13) and direct vasodilator (1, 3, 14) actions, however nitroglycerin-like or not it may be. Uchida (4) reported a decrease in peripheral vascular resistance in anesthetized dogs with doses of 100 ,ug/kg or more of nipradilol. However, in the present experi ments, total peripheral resistance remained practically unchanged in all the doses examined (data are not shown). Therefore, it appears that the alpha-adrenoceptor blocking and direct vasodilator actions on arterial beds may not much contribute to the hypotensive effect either. Thus, instead, the reduction in COP following a decrease in VR would be a major cause of the acute hypotensive effect of nipradilol, as suggested by previous investigators (6) .
